Related Experiment Video
Updated: Jun 25, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
TACE Combined with Ralox-HAIC (Oxaliplatin Puls Raltitrexed) and System Therapy in Patients with Unresectable
Ruiqing Liu1, Guangshao Cao1, Lupeng Li1
1Department of Interventional Oncology, Henan Provincal People's Hospital, Zhengzhou, People's Republic of China.
Transarterial Chemoembolization (TACE) combined with Hepatic Arterial Infusion Chemotherapy (Ralox-HAIC) and systemic therapy shows high response rates for unresectable Hepatocellular Carcinoma (uHCC). This combination therapy offers a manageable safety profile, suggesting potential for future clinical trials.
Area of Science:
- Hepatobiliary Malignancies
- Interventional Oncology
- Medical Oncology
Background:
- Unresectable Hepatocellular Carcinoma (uHCC) presents significant treatment challenges.
- Current treatment strategies for uHCC require continuous innovation to improve patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of Transarterial Chemoembolization (TACE) combined with Hepatic Arterial Infusion Chemotherapy (Ralox-HAIC) and systemic therapy.
- To assess the impact of this combined treatment approach on Objective Response Rate (ORR), Progression-Free Survival (PFS), and Overall Survival (OS) in patients with uHCC.
Main Methods:
- Retrospective analysis of clinical data from 36 patients with uHCC treated between January 2023 and December 2024.
- Patients received TACE combined with Ralox-HAIC (Oxaliplatin + Raltitrexed) followed by sequential systemic therapy.
- Primary endpoint: ORR. Secondary endpoints: PFS, OS, and safety.
Main Results:
- High Objective Response Rate (ORR) of 77.78% and Disease Control Rate (DCR) of 91.67%.
- Median Progression-Free Survival (PFS) of 12.0 months and median Overall Survival (OS) of 19.0 months.
- One-year survival rate of 89% and two-year survival rate of 38%, with no Grade 4 adverse events or treatment-related deaths.
Conclusions:
- The combination of TACE, Ralox-HAIC, and systemic therapy is effective in managing uHCC.
- This treatment regimen demonstrates a favorable safety profile.
- Further prospective studies are warranted to validate these findings.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
